WIL-1901 is under clinical development by Whan In Pharm and currently in Phase I for Dementia Associated With Alzheimer’s Disease. According to GlobalData, Phase I drugs for Dementia Associated With Alzheimer’s Disease have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how WIL-1901’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

WIL-1901 overview

WIL-1901 is under development for the treatment of dementia associated with Alzheimer's disease. It is a incrementally modified drug (IMD) candidate.

Whan In Pharm overview

Whan In Pharm (Whan In Pharma) develops, manufactures and supplies pharmaceutical products. The company’s product range includes anti-depressants, anti-psychotics, nootropics and anti-dementia, anti-epileptics, antibiotics, anti-viral agents, anti-histamines, anti-inflammatory drugs and analgesics. It also produces drugs for the treatment of central nervous system, cardiovascular, gastrointestinal, metabolic and respiratory disorders. Whan In Pharma is investigating therapies against dementia, Parkinson’s disease, cancer, epilepsy, alcoholism, depression, and chronic arterial obstruction. The company offers its products in the forms of tablets, capsules and injections. It works in collaboration with companies across Europe, the US, and India. Whan In Pharm is headquartered in Seoul, South Korea.

For a complete picture of WIL-1901’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.